MARKET

ONCY

ONCY

Oncolytics Biotech Inc
NASDAQ
0.8710
-0.0323
-3.58%
Pre Market: 0.8700 -0.001 -0.11% 07:31 05/14 EDT
OPEN
0.8827
PREV CLOSE
0.9033
HIGH
0.9000
LOW
0.8707
VOLUME
1.52K
TURNOVER
0
52 WEEK HIGH
1.510
52 WEEK LOW
0.3258
MARKET CAP
101.15M
P/E (TTM)
-2.9033
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ONCY last week (0504-0508)?
Weekly Report · 3d ago
Lake Street Sticks to Its Buy Rating for Oncolytics Biotech (ONCY)
TipRanks · 05/05 14:55
Analysts Have Conflicting Sentiments on These Healthcare Companies: Oncolytics Biotech (ONCY), BioMarin Pharmaceutical (BMRN) and Tactile Systems Technology (TCMD)
TipRanks · 05/05 10:31
Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks
Benzinga · 05/04 16:42
Oncolytics Biotech Highlights Strong Pelareorep Data in Colorectal Cancer
TipRanks · 05/04 13:31
Oncolytics Biotech Announces Its Data From REO 022 Trial In Metastatic Colorectal Cancer Shows 19.5-Month Median Duration Of Response In Second-Line KRAS-Mutant MSS mCRC Participants
Benzinga · 05/04 13:02
Oncolytics says pelareorep combo shows 19.5-month response duration in Phase 2 mCRC study
PUBT · 05/04 13:00
ONCOLYTICS BIOTECH INC - 2L KRAS-MUTANT MSS MCRC DEMONSTRATES 3-4X IMPROVEMENT IN DURATION OF RESPONSE VS. HISTORICAL 4-6 MONTH BENCHMARK
Reuters · 05/04 13:00
More
About ONCY
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Webull offers Oncolytics Biotech Inc stock information, including NASDAQ: ONCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONCY stock methods without spending real money on the virtual paper trading platform.